Harry Kirsch - Novartis Chief Officer
| NVSEF Stock | USD 98.25 6.75 6.43% |
Executive
Mr. Harry Kirsch was Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Companys Pharmaceuticals Division. Under his leadership, the divisions core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter Gamble in the United States, where he was CFO of PGs global pharmaceutical business. Prior to that, he held finance positions in various categories of PGs consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany. From 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. since 2013.
| Age | 58 |
| Tenure | 11 years |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Rebecca Edwards | Organon Co | N/A | |
| Steven Baert | Novartis AG ADR | 45 | |
| Aaron Falcione | Organon Co | 53 | |
| Thomas Larsen | Sanofi ADR | 50 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Vasant MD | Novartis AG ADR | 48 | |
| Adrian Kemp | AstraZeneca PLC ADR | N/A | |
| Geralyn Ritter | Organon Co | 55 | |
| Heiko Schipper | Bayer AG | 54 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Klaus Moosmayer | Novartis AG ADR | 56 | |
| Jennifer Halchak | Organon Co | N/A | |
| Dmitri MD | Scilex Holding | 65 | |
| Steffen Lang | Novartis AG ADR | 57 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Elaine Chan | Scilex Holding | N/A | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Joseph Morrissey | Organon Co | 59 | |
| Jeffrey Pott | AstraZeneca PLC | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor, Chief Sandoz | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| MarieFrance Tschudin, Pres Officer | ||
| Paul Penepent, Head Accounting | ||
| Samir MD, Global Relations | ||
| Robert PharmD, Chief Officer | ||
| Klaus Moosmayer, Chief Ethics Risk and Compliance Officer, Member of the Executive Committee | ||
| Karen Hale, Chief Officer | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Harry Kirsch, Chief Officer |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 207.39 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.00 X | |||
| Price To Book | 3.22 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Novartis Pink Sheet
Novartis financial ratios help investors to determine whether Novartis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novartis with respect to the benefits of owning Novartis security.